The Effect of Agomelatine or Fluoxentine on Heart Rate Variability in Patients With Major Depressive Disorder

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-10-31

Study Completion Date

2007-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Phase advance of HRV will be anticipated in agomelatine group. It is anticipated that both agomelatine and floxentine will increase HRV at the end of the treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Double-blind, Placebo-controlled Study of Antidepressant Augmentation With Agomelatine

NCT04589143

Major Depressive Disorder

COMPLETED PHASE4

SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety

NCT07174947

Hepatobiliary Malignancy Fluoxetine Anxiety Disorders +1 more

NOT_YET_RECRUITING PHASE2

Antidepressants to Promote Recovery of Cardiac Patients Suffering From Depression

NCT01099592

Acute Coronary Syndrome Major Depressive Episode

TERMINATED PHASE4

Aripiprazole for the Augmentation of Antidepressant Therapy

NCT01429831

Major Depressive Disorder

COMPLETED PHASE4

A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy

NCT04532749

Depressive Disorder, Major

TERMINATED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Phase advance of HRV will be anticipated in agomelatine group. It is anticipated that both agomelatine and floxentine will have equal efficacy in improvement of depressive symptoms and increasement of HRV at the end of the treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depressive Disorder, Major

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Agomelatine

Intervention Type DRUG

Fluoxentine

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Asian patients
* Male or female
* 18 to 65 years outpatients
* DSM-IV-TR criteria for Major Depressive Disorder

Exclusion Criteria

* Patients with cardiac conditions and other physical conditions contraindicated for drug study
* Shift worker
* Patients known to be non-responders to fluoxetine treatment
* Pregnancy, or breastfeeding

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No